Group 1 - The core point of the article is that Ying Sheng Science (00209) has completed a placement agreement, issuing a total of 30.9515 million shares at a price of HKD 0.35 per share, which represents approximately 16.67% of the company's issued share capital after the placement [1] Group 2 - The placement was completed on September 19, 2025, and all conditions outlined in the placement agreement have been met [1] - The shares were allocated to no fewer than six subscribers [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示不會就本公告全部或任何部份內容而產 生或因依賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考用途，並不構成收購、購買或認購本公司任何證券之邀請或要約。 WINSHINE SCIENCE COMPANY LIMITED 209 完成根據一般授權配售新股份 配售代理 完成根據一般授權配售新股份 董事會欣然宣佈，配售協議所載的所有條件均已達成，且配售事項已於二零二五年九月 十九日根據配售協議的條款及條件完成（「完成」）。根據配售協議，本公司已按每股配售 股份0.35港元之配售價，向不少於六名承配人配發及發行合共30,951,496股配售股份，相 當於本公告日期本公司已發行股本（經配發及發行配售股份擴大後）約16.67%。 - 1 - * 所得款項用途 配售事項的所得款項總額為10,833,023.60港元，扣除費用及開支後，配售事項的所得款項 淨額約為10,320,000.00港元。配售事項所得款項淨額擬作以下用途：(i)約50%用於償還貸 款；(ii)約10%用於支付未清償核數費用；(i ...

Group 1 - The core point of the article is that Ying Sheng Science (00209) has engaged in a share placement agreement, raising approximately HKD 10.83 million through the issuance of new shares at a price of HKD 0.350 per share [1] - On September 16, shareholders transferred shares worth HKD 3.7261 million from Hope Securities to Bank of China (Hong Kong), representing 8.45% of the total shares [1] - The share placement involves issuing 30.9515 million new shares, which accounts for about 16.67% of the company's total issued shares post-placement [1] Group 2 - The estimated net proceeds from the placement, after deducting all related expenses, are approximately HKD 10.32 million [1] - The company plans to allocate around 50% of the net proceeds for loan repayment and the other 50% for operational funds and general corporate purposes [1]

Core Viewpoint - The recent stock transfer and placement agreement of Ying Sheng Science indicates significant financial activities and capital restructuring within the company, highlighting its strategic focus on debt repayment and operational funding [1] Group 1: Stock Transfer - On September 16, shareholders of Ying Sheng Science transferred shares from Hope Securities to Bank of China (Hong Kong), with a market value of HKD 3.7261 million, accounting for 8.45% of the total shares [1] Group 2: Placement Agreement - On September 11, Ying Sheng Science announced a placement agreement with a placement agent, agreeing to place 30.9515 million new shares at a price of HKD 0.350 per share, representing approximately 16.67% of the enlarged issued share capital post-placement [1] - The total nominal value of the placement shares will be HKD 309,500 [1] - The total proceeds from the placement are estimated to be HKD 10.833 million, with a net amount of approximately HKD 10.32 million after deducting all related expenses [1] Group 3: Use of Proceeds - Approximately 50% of the net proceeds from the placement is intended for loan repayment, while the other 50% is earmarked for the group's working capital and general corporate purposes [1]

瀛晟科学宣布，将按每股0.350港元的价格配售3095.15万股新股份，占配售扩大后总股本的约16.67%。 配售所得款项总额为1083.3万港元，净额约1032万港元，其中约50%将用于偿还贷款，其余用于集团营 运资金及一般企业用途。 ...

Group 1 - The company, Ying Sheng Science (00209), announced a placement agreement with a placement agent to issue 30.9515 million new shares at a price of HKD 0.350 per share, representing approximately 16.67% of the company's total issued shares post-placement [1] - The placement price of HKD 0.350 per share is at a premium of about 1.45% compared to the closing price of HKD 0.345 per share on the date of the placement agreement [1] - The total nominal value of the placement shares will be HKD 30.95 million, with total proceeds estimated at HKD 10.833 million, and the net proceeds after all related expenses are expected to be approximately HKD 10.32 million [1] Group 2 - Approximately 50% of the net proceeds will be used to repay loans, while the remaining 50% will be allocated for the group's working capital and general corporate purposes [1]

Core Viewpoint - Ying Sheng Science (00209) announced a placement agreement to issue 30.9515 million new shares at a price of HKD 0.350 per share, representing approximately 16.67% of the company's total issued shares post-placement [1] Group 1: Placement Details - The placement price of HKD 0.350 per share is at a premium of approximately 1.45% compared to the closing price of HKD 0.345 on the date of the placement agreement [1] - The total nominal value of the placement shares will be HKD 30.95 million [1] - The total proceeds from the placement are estimated to be HKD 10.833 million, with a net amount of approximately HKD 10.32 million after deducting all related expenses [1] Group 2: Use of Proceeds - Approximately 50% of the net proceeds is intended for loan repayment, while the other 50% is planned for general working capital and corporate purposes [1]

Core Viewpoint - Ying Sheng Science (00209.HK) announced a placement agreement to issue 30.95 million new shares at a price of HKD 0.350 per share, representing a 1.45% premium over the closing price on the agreement date and a 7.16% discount to the average closing price over the preceding five trading days [1] Group 1: Placement Details - The placement will be fully underwritten by the placement agent and will be made to no fewer than six subscribers [1] - The new shares represent 20% of the existing issued share capital as of the announcement date and approximately 16.67% of the enlarged issued share capital post-placement [1] - The total nominal value of the placement shares will be HKD 30,950 [1] Group 2: Financial Implications - The total proceeds from the placement are estimated to be HKD 10.83 million, with a net amount of approximately HKD 10.32 million after deducting all related expenses [1] - Approximately 50% of the net proceeds will be used to repay loans, and the remaining 50% will be allocated for working capital and general corporate purposes [1]

香港交易及結算所有限公司及聯交所對本公告之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示不會就本公告全部或任何部份內容而產生或因依賴該等內 容而引致之任何損失承擔任何責任。 本公告僅供參考用途，並不構成收購、購買或認購本公司任何證券之邀請或要約。 WINSHINE SCIENCE COMPANY LIMITED 209 根據一般授權配售新股份 配售代理 IMAGI BROKERAGE LIMITED 於二零二五年九月十一日（交易時段後），本公司與配售代理訂立配售協議，據此，配 售代理同意按悉數包銷基準按每股配售股份0.350港元之價格為及代表本公司向不少於 六名承配人配售30,951,496股新股份。配售股份將根據一般授權配發及發行。 配售價每股配售股份0.350港元較：(i)於配售協議日期在聯交所所報之收市價每股股份 0.345港元溢價約1.45%；及(ii)於緊接配售協議日期前五個連續交易日在聯交所所報每 股股份之平均收市價0.377港元折讓約7.16%。 假設於本公告日期與配售事項完成之間，本公司已發行股本將不會發生變動，配售事 項項下之30,951,496股新股份佔於本公告日期本公司現 ...

瀛晟科学发布公告，李忠海先生(李先生)于2025年9月3日透过Hurray Talent(一间由李先生全资拥有的公 司)出售总数为3739.29万股本公司股份(相当于本公司已发行股本约24.16%)予Peak Access(一间由王女士 全资拥有的公司)。出售事项完成后，本公司的主要股东由Hurray Talent变更为Peak Access。 香港联交所最新资料显示，9月5日，瀛晟科学(00209)股东将股票由由希望证券转入中策富汇证券，转 仓市值1804万港元，占比24.80%。 ...